Plain-English translation of NCT07383025 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a real-world study of , a medication approved to treat obstructive hypertrophic cardiomyopathy (a condition where the heart muscle becomes thickened and blocks blood flow). Researchers in Japan are enrolling about 200 patients who are already taking this medication to carefully track how well it works and how safe it is outside of a controlled clinical trial setting.
Even after a medication is approved, doctors and manufacturers need to continue monitoring how it performs in real patients with different health situations. This study will help ensure the medication is working safely and effectively for people living with this heart condition in Japan.
You likely qualify if…
You likely don't qualify if…
As a participant, you would continue taking your medication as prescribed by your doctor while the study team monitors your health and gathers information about how the treatment is working for you. The study will track your progress over time using your medical records and visits to your healthcare provider—you're not undergoing a new experimental treatment, but rather being closely followed as part of a safety and effectiveness registry.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
Japan
Enrollment target
~200 participants
Started
May 2025
Primary completion
November 2029
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
BMS Study Connect Contact Center www.BMSStudyConnect.com
Bristol-Myers Squibb
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.